Currently, two anti-programmed cell death-1 (PD-1) inhibitors and two anti-programmed cell death ligand-1 (PD-L1) inhibitors have been approved for treating NSCLC; the former includes nivolumab and pembrolizumab, and the latter are atezolizumab and durvalumab. Here, PDCD1 is linked to non-small cell lung carcinoma.